In a significant cross-border collaboration, Australian biotech company AdAlta (ASX:1AD) and its cellular immunotherapy subsidiary, AdCella, have entered into an agreement with Shanghai Cell Therapy Group (SHcell) to co-develop and commercialise a cutting-edge cancer treatment, BZDS1901, outside China. …
AdAlta and SHcell launch cancer collaboration to progress breakthrough CAR-T therapy
January 2, 2026 Australian BiotechBioPharmaDispatch Executive
Latest Video
Georgia Forrest
New Stories
-
The 'Dispatched' Podcast - Episode 1, Series 5
January 23, 2026 - - Podcast -
AusBiotech announces new advisory groups to support the life sciences sector
January 22, 2026 - - Latest News -
Specialised Therapeutics brings new hope to women with HER2-positive breast cancer in Thailand
January 22, 2026 - - Latest News -
New funding deal brings next-generation cystic fibrosis treatments closer for New Zealanders
January 22, 2026 - - Latest News -
For almost all of the last 40 years, Governments have aimed to make medicines less affordable, for everyone but them
January 22, 2026 - - Latest News -
argenx deepens Australian research footprint with Monash partnership
January 21, 2026 - - Latest News -
New data reinforce promise of cancer vaccine, with Australia playing a key role
January 21, 2026 - - Latest News